OK, so there's a guy over on StockTwits saying that Vascepa was rejected by China's NRDL for this year, and that future chances to get approved are very low. No idea how he knows this, or if he is just speculating. But he seems to think that many people were already aware of it (hence maybe the stock price action?). Not sure what to think, but he's been on the AMRN board for a while (BioForGood).
Market Data 
Markets 
AI
